By Katherine Hamilton
Ardelyx shares fell after the company missed analysts' expectations that it would post a profit.
The stock fell 13% to $5.89 Friday. Shares are still up 2% over the past 12 months.
The biopharmaceutical company recorded a loss of $407,000 in the fourth quarter, which came out to be breaking even on a per-share basis.
Analysts polled by FactSet had been expecting net income of $4,500, or one cent a share.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 20, 2026 13:38 ET (18:38 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.